Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore. More
- ADVERTISEMENT
-
Sponsored By:
-
Sponsored By:
- Poll of the Day
- Partners
- ADVERTISEMENT
- More Financial News
- Top 5 Zacks #1 Ranked High Yield Mutual Funds - Best of Funds
- Another Contract for KBR - Analyst Blog
- How to Beat THIS Market - Weekend Wisdom
- Promising Data on ONCY's Reolysin - Analyst Blog
- Video Game Sales Plunge in April - Analyst Blog
















